Previous meta-analyses did not show any increased risk of adverse outcomes in women with IBD during pregnancy who had anti-TNF-α therapy compared with the those not exposed to anti-TNF-α drugs [11, 12]. This evidence concerns the gene TNF and inflammatory bowel disease.